{"lc": 1, "type": "constructor", "id": ["langchain", "schema", "document", "Document"], "kwargs": {"metadata": {"source": "/home/guanzhideng145/research/ip_portal/patent_kg/patents/721-US20210060002A1(Pending) not sealed.pdf"}, "page_content": "3. The method of claim 2, wherein the analogue berbamine has a structure of Formula (IIb), (IIIb) or\n\nFormula (IT)\n\n\u548c yo | | Car \u00b0 S LZ \u2018oO NN mr OL \u5de5 SS Oo ON\n\nFormula (IIb)\n\nFormula (IIb)\n\nof\n\n(III)\n\n(IV)\n\nof (Vb):\n\ncA\n\nUS 2021/0060002 A1\n\nMar. 4 , 2021\n\n13\n\ncontinued\n\ncontinued\n\nFormula ( IVb )\n\nH\n\n. ... 1111\n\nN\n\nOH\n\nNO2\n\nBr\n\n4. The method of claim 1 , wherein berbamine or its\n\nanalogue further inhibits the entry of an enterovirus and / or\n\na lentivirus in host cells of the subject .\n\n5. The method of claim 1 , wherein berbamine or its\n\nanalogue is administered to the subject by a route selected\n\nfrom a group consisting of oral delivery , intravenous deliv\n\nery , intradermal delivery , intraperitoneal delivery and intra\n\nmuscular delivery .\n\n6. The method of claim 1 , wherein the subject is a\n\nmammal and the berbamine or its analogue is administered\n\nto the subject at a dose of about 20 mg / kg to about 50 mg / kg .\n\n7. The method of claim 1 , wherein the subject is human\n\nand berbamine or its analogue is administered to the subject\n\nat a dose of about 20 mg / kg to about 50 mg / kg .\n\n8. The method of claim 1 , wherein berbamine or its\n\nO\n\nanalogue is administered in combination with a compound\n\nselected from the group consisting of the following com\n\npounds and a derivative thereof :\n\na\n\nBr ,\n\nNH\n\nOH ,\n\nC1\n\nUS 2021/0060002 A1\n\nMar. 4, 2021\n\n13\n\n-continued\n\n-continued\n\nFormula (IVb)\n\non on A, o SN ; Nt OL we 0 0. 0 AAA SS\n\n4. The method of claim 1, wherein berbamine or analogue further inhibits the entry of an enterovirus and/or lentivirus in host cells of the subject.\n\n5. The method of claim 1, wherein berbamine or its analogue is administered to the subject by a route selected from a group consisting of oral delivery, intravenous deliv- ery, intradermal delivery, intraperitoneal delivery and intra- muscular delivery.", "type": "Document"}}